COVID Cases In Mumbai Rise By 79% In Last 24 Hours, 852 Cases Reported


New Delhi: Mumbai, the capital of Maharashtra, on Wednesday witnessed 852 COVID-19 fresh cases, the highest daily rise after July 1, and a single death, With this, the number of active patients of Coronavirus in Mumbai has increased to 11,29,285 and death count to 19,661, the city civic body BMC said. In the last 24 hours, there has been a jump of 79 percent in the cases of coronavirus. This is the highest number of cases reported in a single day after July 1. 

On July 1, 978 cases were reported in Mumbai and there were two deaths. Barring the first two days of this month, Mumbai has reported over 400 coronavirus infections daily. 

The number of cases increased by about 79 per cent in the last 24 hours as compared to 476 cases reported on Tuesday. 

The Brihanmumbai Municipal Corporation (BMC) bulletin states that the number of active cases has increased from 3,500 to 3,545. A total of 9,670 corona tests were conducted in the last 24 hours.

Significantly, on Wednesday, 1,847 cases of coronavirus infection were reported in Maharashtra and seven patients died. With the new cases reported on Wednesday, the number of infected increased to 80,64,336 and the death toll reached 1,48,157. At present, 11,889 patients under treatment for COVID-19 are present in Maharashtra.

Meanwhile, The government has authorised Biological E’s Corbevax as a prophylactic dosage for persons over the age of 18 who have been completely vaccinated with either Covishield or Covaxin, according to official sources, news agency PTI reported.

Also Read: Govt Approves Biological E’s Corbevax As Booster Dose For Adults Vaccinated With Covaxin, Covishield

This is the first time in the country that a booster dosage different from the one used for initial immunisation against Covid has been permitted.

According to reports, the Union Health Ministry’s clearance is based on recent recommendations from the COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI).

“Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines for those aged above 18 years enabling use of  Corbevax as a heterologous COVID-19 vaccine for precaution dose administration in this age group,” the sources were quoted by PTI in its report.